Here’s a startling revelation: obesity might be silently accelerating the progression of Alzheimer’s disease, and this connection is now backed by groundbreaking research. But here’s where it gets controversial—while obesity has long been linked to various health issues, its direct impact on Alzheimer’s progression through blood biomarkers is a relatively unexplored territory. And this is the part most people miss: the relationship isn’t just about lifestyle; it’s about measurable, biological changes happening in the brain and bloodstream.
In a pioneering study, researchers tracked biomarker trajectories over five years in individuals with Alzheimer’s disease (AD). What they found was eye-opening: participants with obesity showed significantly steeper rises in key biomarkers like pTau217, neurofilament light chain (NfL), and amyloid burden compared to those without obesity. Specifically, blood-based biomarker (BBM) values climbed 29% to 95% faster in obese individuals, while amyloid accumulation on PET scans increased by 3.7%, and plasma NfL levels rose 24% more rapidly.
Here’s the bold part: these findings challenge the conventional wisdom that obesity might somehow protect against Alzheimer’s in its early stages. Initial cross-sectional analysis suggested that higher body mass index (BMI) correlated with lower BBM values, which could misleadingly imply reduced Alzheimer’s pathology. However, the longitudinal data tells a different story. ‘By relying on baseline measurements alone, you could be fooled into thinking obesity is less harmful,’ explained Dr. Soheil Mohammadi, the study’s lead author. ‘It’s the long-term trends that reveal how obesity truly impacts Alzheimer’s development.’
The study, presented at the Radiological Society of North America (RSNA) annual meeting, utilized amyloid PET imaging and repeated plasma sampling to monitor biomarkers like pTau217, NfL, and GFAP over time. The divergence in biomarker trajectories between obese and non-obese participants was striking, with plasma pTau217 levels rising up to 100% faster in those with obesity. Even more surprising was the sensitivity of blood biomarkers compared to PET imaging in tracking disease progression. ‘The fact that blood biomarkers can predict the influence of obesity more accurately than PET scans is what truly astonished me,’ said Dr. Cyrus Raji, the study’s senior author.
These findings aren’t just academic—they have real-world implications. According to the 2024 Lancet Commission report, nearly half of Alzheimer’s risk is tied to modifiable factors, including obesity. ‘If we can reduce these risk factors, we could significantly lower Alzheimer’s cases or delay its onset,’ Mohammadi emphasized. The study also opens the door for future research, particularly in tracking how weight loss drugs might impact Alzheimer’s biomarkers. ‘We now have the tools—blood biomarkers and MRI scans—to monitor both molecular pathology and brain degeneration in response to treatments,’ Raji added. ‘This is foundational for the next wave of Alzheimer’s research and clinical trials.’
But here’s the thought-provoking question: If obesity is such a significant risk factor for Alzheimer’s, why isn’t it more prominently featured in public health campaigns? And could weight loss interventions become a standard part of Alzheimer’s prevention strategies? Share your thoughts in the comments—this is a conversation that deserves to be heard.
